PT  - JOURNAL ARTICLE
AU  - Conzentino, Marcelo S.
AU  - Forchhammer, Karl
AU  - Souza, Emanuel M
AU  - Pedrosa, Fábio O.
AU  - Nogueira, Meri B.
AU  - Raboni, Sônia M.
AU  - Rego, Fabiane G. M.
AU  - Zanette, Dalila L.
AU  - Aoki, Mateus N.
AU  - Nardin, Jeanine M.
AU  - Fornazari, Bruna
AU  - Morales, Hugo M. P.
AU  - Celedon, Paola A. F.
AU  - Lima, Carla V. P.
AU  - Mattar, Sibelle B.
AU  - Lin, Vanessa H.
AU  - Morello, Luis G.
AU  - Marchini, Fabricio K.
AU  - Bueno, Lucas Bochnia
AU  - Reis, Rodrigo A.
AU  - Huergo, Luciano F.
TI  - Antigen production and development of an indirect ELISA based on the nucleocapsid protein to detect human SARS-CoV-2 seroconversion
AID  - 10.1101/2021.02.19.21252100
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.19.21252100
4099  - http://medrxiv.org/content/early/2021/02/23/2021.02.19.21252100.short
4100  - http://medrxiv.org/content/early/2021/02/23/2021.02.19.21252100.full
AB  - Serological assays are important tools to identify previous exposure to SARS-CoV-2, helping to track COVID-19 cases and determine the level of humoral response to SARS-CoV-2 infections and/or immunization to future vaccines. Here the SARS-CoV-2 nucleocapsid protein was expressed in Escherichia coli and purified to homogeneity and high yield using a single chromatography step. The purified SARS-CoV-2 nucleocapsid protein was used to develop an indirect enzyme-linked immunosorbent assay for the identification of human SARS-CoV-2 seroconverts. The assay sensitivity and specificity were determined analyzing sera from 140 PCR-confirmed COVID-19 cases and 210 pre-pandemic controls. The assay operated with 90% sensitivity and 98% specificity; identical accuracies were obtained in head-to-head comparison with a commercial ELISA kit. Antigen coated plates were stable for up to 3 months at 4°C). The ELISA method described is ready to mass production and will be an additional toll to track COVID-19 cases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by UFPR, CNPq, CAPES, Fundacao Araucaria and the Alexander von Humboldt FondationAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Ethics Review Board of CHC/UFPR (n# 30578620.7.0000.0008) approved this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesI agree